EU approves Combo-Drug for Metastatic Colorectal Cancer

28/04/2016 - 2 minutes

Servier sees one of its combo-drug (trifluridine/tipiracil) approved by the European Commission, after showing a 2 month improvement in overall survival for metastatic Colorectal cancer.

servier_colorectal_cancer_europe_lonsurfThe largest private Pharma from France, Servier has well-known stake in innovative oncology therapies due to its role in the restructuring of Cellectis as a universal CAR-T Biotech – which looks extremely promising.

However, Servier has other programmes in cancer. One of those was the development of trifluridine/tipiracil, which Servier licensed from Taiho Pharmaceutical (Japan) for €113.9M upfront.

The drug was now approved by the European Comission (EC) for treatment of metastatic colorectal cancer (mCRC), after a positive recommendation by the EMA. It will be marketed under the trade name of Lonsurf.

This approval follows a phase III trial (RECOURSE) with 800 patients that had been previously treated without success (refractory).

The drug works by directly attacking the DNA of the tumor cells, reducing their growth.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member